Results before and 32 weeks after treatment with rosiglitazone and insulin or placebo and insulin
| Rosiglitazone and insulin | Placebo and insulin | |||||
|---|---|---|---|---|---|---|
| Baseline | Week 32 | Baseline | Week 32 | |||
| Weight (kg) | 97.2 ± 11.8 | 100.6 ± 16.0* | 96.4 ± 12.2 | 99.1 ± 15.0* | ||
| BMI (kg/m2) | 32.7 ± 5.4 | 34.0 ± 7.4* | 31.1 ± 3.1 | 32.0 ± 4.2* | ||
| Systolic blood pressure (mmHg) | 137.4 ± 15.6† | 128.8 ± 14.8* | 125.8 ± 10.0 | 127.5 ± 14.0 | ||
| Diastolic blood pressure (mmHg) | 87.2 ± 9.4 | 79.4 ± 7.2‡ | 84.7 ± 7.0 | 83.2 ± 7.1 | ||
| Insulin dose (units/day) | 77.5 ± 28.6 | 75.3 ± 33.1 | 74.0 ± 33.8 | 82.0 ± 48.9* | ||
| Fasting plasma glucose (mg/dl) | 172.6 ± 68.3 | 153.3 ± 66.4 | 185.8 ± 90.6 | 173.4 ± 64.8 | ||
| A1C (%) | 7.9 ± 1.3 | 6.9 ± 0.7‡ | 7.7 ± 0.8 | 7.0 ± 0.9‡ | ||
| Total cholesterol (mg/dl) | 201.9 ± 37.6† | 195.2 ± 37.5§ | 177.9 ± 33.1 | 175.1 ± 31.7 | ||
| LDL cholesterol (mg/dl) | 117.8 ± 32.0 | 120.1 ± 35.0 | 103.4 ± 25.2 | 102.6 ± 25.4 | ||
| HDL cholesterol (mg/dl) | 53.9 ± 20.5 | 53.6 ± 19.4 | 47.8 ± 15.0 | 49.1 ± 15.8 | ||
| VLDL cholesterol (mg/dl) | 15.8 ± 13.2 | 16.4 ± 9.8 | 13.8 ± 9.4 | 14.6 ± 15.6 | ||
| Triglycerides (mg/dl) | 108.1 ± 64.6 | 101.8 ± 53.8 | 92.8 ± 38.9 | 85.4 ± 39.7 | ||
| VLDL triglycerides (mg/dl) | 66.8 ± 57.6 | 61.9 ± 46.6 | 55.8 ± 31.6 | 48.8 ± 33.0 | ||
| Hemoglobin (gm/dl) | 14.4 ± 1.5 | 13.6 ± 1.9‡§ | 14.5 ± 1.0 | 14.5 ± 1.0 | ||
| Hematocrit (%) | 42.0 ± 3.9 | 39.8 ± 5.1‡§ | 42.3 ± 3.0 | 42.2 ± 2.9 | ||